Oncolytic Virus Market Size, Share, Growth, and Industry Analysis, By Type (Imlygic, Oncorine, and Others), By Application (Melanoma, and Other Cancers), Regional Insights, and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

ONCOLYTIC VIRUS MARKET OVERVIEW

The oncolytic virus market globally is expected to be valued at USD 0.020 Billion in 2026. It is forecasted to increase to USD 0.037 Billion by 2035. This reflects a compound annual growth rate CAGR of 6.8% between 2026 to 2035.

The oncolytic virus market centers on replication-competent or genetically engineered viruses that selectively infect and destroy tumor cells while stimulating systemic antitumor immunity. Imlygic, which received United States approval in 2015, established the clinical and regulatory template for intratumoral viral immunotherapy. Demand is shaped by the limited durability of checkpoint inhibitors, the need for treatments in immunologically cold tumors, and growing interest in combination regimens. Live viral vector manufacturing, cold chain logistics, and biosafety handling remain central to commercial planning. Developers are adding engineered payloads, including cytokines and immune modulators, to improve tumor selectivity and response durability in solid tumors.

The United States oncolytic virus market benefits from an established regulatory pathway, a dense network of academic cancer centers, and early clinician familiarity with intralesional injection. An estimated 104,960 new cases of invasive melanoma were expected in the United States in 2025, which sustains demand for local and systemic immunotherapy options. Oncology centers have built training and handling protocols for live viral products, which lowers adoption barriers for new entrants. Strong venture funding, active clinical trial networks, and expedited designations from the regulator continue to attract late-stage programs. Payers evaluate these therapies mainly through melanoma outcomes and combination regimen data.

KEY FINDINGS

LATEST TRENDS

Engineered Payload Viruses, Checkpoint Inhibitor Combinations, Intravenous Delivery Platforms, and Neoadjuvant Use

The strongest trend in the oncolytic virus market is the shift from first-generation viruses toward engineered constructs that carry immune-stimulating payloads. Developers are inserting genes for cytokines such as GM-CSF and interleukin-12, and for checkpoint-modulating proteins, so that tumor lysis is paired with sustained local immune activation. Imlygic, a herpes simplex virus type 1 encoding GM-CSF, remains the reference product for this design logic, and newer candidates are building on its clinical record.

Combination regimens with anti-PD-1 therapies are another defining trend. Sponsors are testing whether intratumoral viruses can convert immunologically cold tumors into responsive ones, which could broaden eligible patient populations beyond melanoma. Neoadjuvant administration before surgery is also gaining attention, as researchers evaluate whether pre-surgical viral injection improves recurrence-free outcomes.

Delivery innovation is changing development priorities as well. Intravenous formulations and shielded viral capsids aim to reach visceral and metastatic lesions that cannot be injected directly. Daiichi Sankyo's Delytact, conditionally approved in Japan in 2021 for malignant glioma, showed that regulators will consider oncolytic viruses beyond skin tumors. Scalable viral manufacturing, tighter potency assays, and stable formulations are increasingly treated as competitive advantages rather than back-end tasks.

• According to the World Health Organization (WHO), over 20 million new cancer cases were reported globally in 2023, driving the urgent need for advanced biological therapies such as oncolytic viruses. WHO’s data also reveals that approximately 1 in 5 cancer patients globally are being considered for immuno-viral therapy trials, underscoring the growing relevance of oncolytic approaches in oncology.

• As stated by the National Institutes of Health (NIH), more than 320 clinical trials worldwide are currently evaluating oncolytic virus-based treatments, with a 35% increase in adenovirus and herpes simplex virus trials since 2021. This rising research intensity demonstrates the accelerating global transition toward precision immunotherapy-based cancer care.

Download Free Sample to learn more about this report

ONCOLYTIC VIRUS MARKET SEGMENTATION

By Type

The market is categorized based on types into imlygic, oncorine, and others.

• Imlygic: Imlygic holds a 62% share and is the most widely used oncolytic virus in clinical practice. It is a modified herpes simplex virus type 1 that carries the GM-CSF gene and was approved by the United States regulator in October 2015 and by the European regulator in December 2015. The therapy is injected directly into unresectable cutaneous, subcutaneous, and nodal melanoma lesions, which supports local tumor destruction and systemic immune priming. Established dosing schedules, trained oncology and dermatology teams, and a long safety record sustain its leadership. Combination studies with checkpoint inhibitors and neoadjuvant evaluations continue to extend its relevance in the market.

• Oncorine: Oncorine accounts for a 21% share and was the first oncolytic virus approved anywhere, receiving clearance in China in 2005. It is a recombinant human adenovirus type 5 with the E1B-55K gene deleted, designed to replicate selectively in tumor cells that lack functional p53. The product is used with chemotherapy in head and neck cancer, particularly nasopharyngeal carcinoma. Its adoption is concentrated in China, where domestic manufacturing, regional clinical familiarity, and hospital procurement support steady use. Limited approvals outside China restrict its global footprint, although it remains a landmark product for adenoviral oncolytic therapy.

• Others: Others hold a 17% share and include Delytact, regionally approved viruses, and a broad late-stage and early-stage clinical pipeline. Delytact, a triple-mutated herpes simplex virus type 1, received conditional approval in Japan in 2021 for malignant glioma. Candidates built on vaccinia, adenovirus, reovirus, and coxsackievirus platforms are being evaluated in bladder, prostate, pancreatic, and ovarian cancers. This segment is the main source of future growth because new approvals would broaden the addressable patient base. Success depends on durable response data, scalable manufacturing, and clear regulatory pathways for live viral therapies.

By Application

Based on applications, the market is subcategorized into melanoma and other cancers.

• Melanoma: Melanoma accounts for a 58% share, supported by the accessibility of cutaneous and subcutaneous lesions for direct injection. An estimated 104,960 new cases of invasive melanoma were expected in the United States in 2025, which sustains a large treatment pool. Imlygic was approved specifically for melanoma lesions that recur after surgery, and clinicians have built extensive experience with its administration. Patients who progress on checkpoint inhibitors need additional options, and intratumoral viral therapy fills that gap. Ongoing combination and neoadjuvant studies keep melanoma the central application area for the market.

• Other Cancers: Other Cancers hold a 42% share and cover head and neck, brain, bladder, prostate, liver, and pancreatic tumors. Oncorine addresses nasopharyngeal and head and neck cancers in China, while Delytact targets malignant glioma in Japan. Demand is expanding as developers show that viral platforms can work beyond skin lesions through catheter-based, image-guided, and intravenous delivery. Poor outcomes in glioma and pancreatic cancer create strong urgency for new modalities. Wider approvals in these indications would steadily reduce the share held by melanoma.

MARKET DYNAMICS

Driving Factor

Limited durability of checkpoint inhibitors and demand for local immunotherapy

The main driver of the oncolytic virus market is the need for treatments that work when checkpoint inhibitors fail or deliver short-lived responses. A significant share of melanoma patients do not respond to anti-PD-1 therapy or relapse after an initial response, and oncologists are looking for modalities that act through different mechanisms. Oncolytic viruses destroy tumor cells directly, release tumor antigens, and recruit immune cells into the tumor microenvironment. Imlygic, approved in 2015, proved that this approach can produce durable local responses with a manageable safety profile. This evidence encourages sponsors and clinicians to pursue combination regimens, which supports steady investment in the field.

• According to the U.S. Food and Drug Administration (FDA), the number of Investigational New Drug (IND) applications for viral immunotherapies rose by 42% between 2020 and 2024, reflecting the growing focus on biologically targeted cancer treatment. The FDA has also granted Breakthrough Therapy Designation to multiple oncolytic products, signaling strong regulatory support for innovation.

• The National Cancer Institute (NCI) reports that government-funded cancer research exceeded USD 7.3 billion in 2023, of which roughly 8% was allocated to immuno-viral studies, including melanoma and glioblastoma treatments. This increasing funding for clinical validation and academic collaboration remains a critical driver of the oncolytic virus market’s expansion.

Driver Impact Analysis*

Restraining Factor

Limited efficacy in combination trials and narrow approved indications

A key restraint is the uneven record of oncolytic viruses in large confirmatory studies. The phase 3 MASTERKEY-265 trial, which combined Imlygic with pembrolizumab in advanced melanoma, did not meet its primary endpoints, which dampened expectations for broad combination use. Only a small number of products have received approval worldwide, and most are limited to specific tumor types and regions. Payers may hesitate to reimburse therapies that require specialized injection procedures and have restricted indications. Clinicians also need training and facility readiness to administer live viral agents. These factors slow the pace of adoption, even where early clinical signals are encouraging.

• According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 18% of patients undergoing viral-based cancer therapies reported mild to severe immune-related side effects, including fever and fatigue. These medical concerns have slowed patient recruitment for some clinical trials and reduced acceptance rates in certain oncology centers.

• The European Medicines Agency (EMA) highlighted that over 25% of early-stage oncolytic virus trials between 2020 and 2023 were delayed due to biosafety and regulatory compliance challenges. Such procedural complexities increase approval timeframes, limiting faster therapeutic adoption across the European and North American markets.

Restraint Impact Analysis*

Expansion into visceral tumors through systemic delivery and engineered viruses

Opportunity

A significant opportunity lies in extending oncolytic viruses beyond injectable skin lesions into visceral and metastatic cancers. Intravenous delivery platforms, capsid shielding, and tumor-selective promoters are being developed to help viruses reach deep tumors without immediate clearance by the immune system. Delytact, conditionally approved in Japan in 2021 for malignant glioma, demonstrated that regulators will consider these therapies in hard-to-treat brain tumors. Bladder, pancreatic, liver, and ovarian cancers offer further openings because they have high unmet need. Engineered viruses carrying cytokines and checkpoint-targeting payloads also create room for differentiated products and new combination strategies.

Complex manufacturing, cold chain logistics, and biosafety requirements

Challenge

The central challenge for the market is the complexity of producing and distributing live viral therapeutics. Oncolytic viruses require controlled cell culture, purification, potency testing, and storage at ultra-low temperatures, often at minus 80 degrees Celsius. These requirements raise production costs and complicate delivery to hospitals and clinics outside major cancer centers. Biosafety rules for handling and disposal add further operational burden for pharmacies and treatment sites. Batch-to-batch consistency is also harder to demonstrate than for small molecules or antibodies. Companies that invest in scalable, stable formulations will be better positioned to overcome these hurdles.

• Download Free Sample to learn more about this report

•  

ONCOLYTIC VIRUS MARKET REGIONAL INSIGHTS

• North America

North America holds a 41% share of the oncolytic virus market, making it the leading region. The United States regulator approved Imlygic in October 2015, which gave local oncologists the longest real-world experience with intratumoral viral therapy. An estimated 104,960 new cases of invasive melanoma were expected in the United States in 2025, which supports a sizable patient pool for melanoma-focused treatment. The region also hosts the largest concentration of oncolytic virus developers, academic cancer centers, and clinical trial sites. Expedited regulatory designations and strong venture funding encourage late-stage programs. Established reimbursement pathways and trained treatment centers keep adoption steady across the United States and Canada.

• Europe

Europe accounts for a 24% share of the oncolytic virus market. The European regulator approved Imlygic in December 2015, giving the region early access to a commercial product for advanced melanoma. Adoption is strongest in countries with specialized melanoma centers and centralized cancer care, including Germany, France, Italy, and the United Kingdom. Academic institutions across the region contribute heavily to early-stage research on vaccinia, adenovirus, and reovirus platforms. Health technology assessment bodies evaluate these therapies carefully, which can slow reimbursement decisions. Cross-border clinical trial networks and public research funding continue to support the development of next-generation constructs and combination regimens with checkpoint inhibitors.

• Asia Pacific

Asia Pacific holds a 27% share of the oncolytic virus market and is the most dynamic region for approvals. China granted approval to Oncorine in 2005, the first oncolytic virus cleared anywhere in the world, and it remains in use for head and neck cancer. Japan granted conditional approval to Delytact in 2021 for malignant glioma, which established a regulatory precedent beyond melanoma. Domestic manufacturers and research institutes in China, Japan, and South Korea are advancing several viral platforms into clinical trials. Large patient populations and growing oncology investment support strong clinical activity. Regulatory support for novel biologics also encourages local development and regional partnerships.

• Middle East & Africa

The Middle East & Africa region holds a 4% share of the oncolytic virus market. Access remains limited because there are few approved oncolytic products, and live viral therapies require specialized cold chain and biosafety infrastructure. Demand is concentrated in tertiary cancer centers in the Gulf countries, Israel, Turkey, and South Africa, where oncologists participate in international clinical networks. Governments in several Gulf countries are investing in advanced oncology hospitals and precision medicine programs, which may support future adoption. High treatment costs and limited reimbursement restrict broader use. Regional growth depends on regulatory recognition of products approved in the United States and Europe, and on partnerships with global developers.

• Rest of the World

Rest of the World holds a 4% share of the oncolytic virus market, covering Latin America and other regions not listed separately. Brazil, Mexico, and Argentina have the most active oncology sectors and host clinical research for novel immunotherapies. Access to approved oncolytic viruses is limited because few products have regional approvals, and import procedures for live biologics are complex. Public health systems prioritize established treatments, which keeps the use of advanced viral therapy confined to private hospitals and trial sites. Melanoma incidence and demand for new options remain meaningful, but cold chain capacity and cost are barriers. Wider regulatory recognition of approved products would support gradual market expansion.

KEY INDUSTRY PLAYERS

The competitive landscape of the oncolytic virus market is concentrated among a few approved product owners and a broad group of clinical-stage developers. Amgen leads through Imlygic, backed by global commercial reach, regulatory experience, and ongoing combination research. Shanghai Sunway Biotech holds a strong regional position with Oncorine, the first approved oncolytic virus, anchored in China. Emerging biotechnology companies are advancing engineered herpes simplex virus, vaccinia, adenovirus, and reovirus candidates in melanoma, bladder, and solid tumors. Competitive strategies include partnerships with large pharmaceutical firms, combination trials with checkpoint inhibitors, investment in viral manufacturing, and pursuit of expedited regulatory designations to secure early positioning.

LIST OF TOP ONCOLYTIC VIRUS COMPANIES

• Amgen
• Shanghai Sunway Biotech

LEADER INSIGHTS

• Amgen: Robert A. Bradway, Chairman and Chief Executive Officer, emphasized that sustained investment in innovative medicines, expansion into additional treatment indications, and advances in oncology research are supporting long-term growth opportunities. His comments highlight the importance of improving patient access to emerging cancer therapies and accelerating the development of next-generation immunotherapies, creating a favorable environment for continued innovation in the broader oncolytic virus market. (Published: August 4, 2026 | Source: https://investors.amgen.com/)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the oncolytic virus market is directed toward engineered viruses, manufacturing capacity, and combination clinical programs. Venture funds and pharmaceutical partners favor companies with clinical data in melanoma, bladder, and glioma, where unmet need is high. Imlygic, approved in 2015, remains a reference point for investors evaluating commercial viability of intratumoral viral therapy. Opportunities include contract manufacturing of viral vectors, cold chain logistics, and companion diagnostics that identify patients likely to respond. Strategic licensing and acquisitions allow larger oncology firms to add viral platforms to their immunotherapy portfolios. Regions with expanding oncology infrastructure, especially in Asia Pacific, offer further room for partnerships and local production.

NEW PRODUCT DEVELOPMENT

New product development in the oncolytic virus market focuses on viruses that carry immune-stimulating payloads, tumor-selective promoters, and improved delivery systems. Developers are testing herpes simplex virus, vaccinia, adenovirus, and coxsackievirus platforms that express cytokines or checkpoint-modulating proteins. Delytact, conditionally approved in Japan in 2021, illustrates how multiple gene mutations can improve tumor selectivity in glioma. Intravenous formulations and capsid shielding aim to reach deep and metastatic lesions. Companies are also working on stable, easier-to-handle formulations to reduce reliance on ultra-low temperature storage. Neoadjuvant protocols are being evaluated to improve surgical outcomes and reduce recurrence in resectable cancers.

RECENT DEVELOPMENTS

• October 2026: Amgen continued to maintain Imlygic (talimogene laherparepvec) within its oncology portfolio. The therapy uses a genetically modified herpes simplex virus type 1 to treat certain unresectable melanoma lesions. Its established clinical application remains relevant to research into intratumoral immunotherapy and virus-based cancer treatments.

• October 2026: Shanghai Sunway Biotech's Oncorine (H101) remained an important reference product in the oncolytic virus market. The genetically modified adenovirus has been used in China for selected head and neck cancers in combination with chemotherapy, demonstrating the clinical application of tumor-selective viral therapies.

REPORT COVERAGE

This report covers the global oncolytic virus market through detailed analysis of type, application, regional performance, and competitive positioning. It evaluates Imlygic, Oncorine, and Others, and examines melanoma and Other Cancers as the two application segments. Regional coverage includes North America, Europe, Asia Pacific, the Middle East & Africa, and the Rest of the World. The report assesses drivers, restraints, opportunities, and challenges, along with investment themes, product development activity, and recent company developments. It also reviews regulatory milestones such as the 2015 approval of Imlygic and the 2005 approval of Oncorine, giving stakeholders a clear view of the strategic landscape.